Related Topics:
Facility ID: 90505BCHMN3132K
Facility Name and Address: BACHEM AMERICAS INC. 3132 KASHIWA ST TORRANCE, CA 90505 Parent Company: NA Industry: Pharmaceutical Preparation Manufacturing (325412) Chemical: N-Methyl-2-pyrrolidone Reports: View TRI Facility profile report for this facility View TRI Form R submissions by this facility |
|
*You can navigate within the map with your mouse. |
Production Related Waste Management for Selected Chemical
lchemid=0000872504
Chart Options1: |
Waste Management Comparison -
Display facility comparison report for this industry and chemical
Pollution Prevention Activities for Selected Chemical
Reporting Year | Section 8.10: Newly Implemented Source Reduction Activity | Section 8.10: Methods to Identify Activity | Section 8.11: Optional Pollution Prevention Information* |
---|---|---|---|
2019 |
Barriers: B3-Barriers to P2 B3 - Concern that product quality may decline as a result of source reduction.
Barriers: B5-Barriers to P2 B5 - Specific regulatory/permit burdens. |
Barriers to P2: B5 - Specific regulatory/permit burdens. - The current process is approved by our customers and regulated by the FDA. Barriers to P2: B3 - Concern that product quality may decline as a result of source reduction. - The current process is approved by our customers and regulated by the FDA. |
|
2018 |
Barriers: B3-Barriers to P2 B3 - Concern that product quality may decline as a result of source reduction.
Barriers: B5-Barriers to P2 B5 - Specific regulatory/permit burdens. |
Barriers to P2: B3 - Concern that product quality may decline as a result of source reduction. - The current process is validated and regulated by the US FDA. Barriers to P2: B5 - Specific regulatory/permit burdens. - The current process is validated and regulated by the US FDA. |
|
2017 |
Barriers: B3-Barriers to P2 B3 - Concern that product quality may decline as a result of source reduction.
Barriers: B5-Barriers to P2 B5 - Specific regulatory/permit burdens. |
Barriers to P2: B3 - Concern that product quality may decline as a result of source reduction. - The current process is approved and regulated by the FDA. Barriers to P2: B5 - Specific regulatory/permit burdens. - The current process is approved and regulated by the FDA. |
|
2016 |
Barriers: B3-Barriers to P2 B3 - Concern that product quality may decline as a result of source reduction.
Barriers: B5-Barriers to P2 B5 - Specific regulatory/permit burdens. |
Barriers to P2: B3 - Concern that product quality may decline as a result of source reduction. - The current process is approved and regulated by the FDA. Barriers to P2: B5 - Specific regulatory/permit burdens. - The current process is approved and regulated by the FDA. |
|
2015 |
Barriers: B3-Barriers to P2 B3 - Concern that product quality may decline as a result of source reduction.
Barriers: B5-Barriers to P2 B5 - Specific regulatory/permit burdens. |
Barriers to P2: B3 - Concern that product quality may decline as a result of source reduction. - The current process is approved and regulated by the FDA. Barriers to P2: B5 - Specific regulatory/permit burdens. - The current process is approved and regulated by the FDA. |
|
2014 |
Barriers: B5-Barriers to P2 B5 - Specific regulatory/permit burdens.
|
Barriers to P2: B5 - Specific regulatory/permit burdens. - due to the fact that Bachem Americas, Inc. is regulated by the FDA. |
|
2013 |
Other Barriers to Source Reduction - Concern that product quality may decline as a result of source reduction and specific regulatory/permit burdens due to the fact that Bachem is regulated by the FDA. |